Updates are available Correction dated 2022-10-20
Click to view Correction: https://doi.org/10.1007/s00277-022-05005-4
-
Authors
Triguero, Ana https://orcid.org/0000-0002-9895-9644
Pedraza, Alexandra
Pérez-Encinas, Manuel
Mata-Vázquez, María Isabel
Vélez, Patricia
Fox, Laura
Gómez-Calafat, Montse
García-Delgado, Regina
Gasior, Mercedes
Ferrer-Marín, Francisca
García-Gutiérrez, Valentín
Angona, Anna
Gómez-Casares, María Teresa
Cuevas, Beatriz
Martínez, Clara
Pérez, Raúl
Raya, José María
Guerrero, Lucía
Murillo, Ilda
Bellosillo, Beatriz
Hernández-Boluda, Juan Carlos
Sanz, Cristina
Álvarez-Larrán, Alberto
,
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/01472, PI18/00205, PI21/0023)
Novartis Pharma
- License Information
-
More Information
Article History
Received: 3 July 2022
Accepted: 17 August 2022
First Online: 30 August 2022
Change Date: 20 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00277-022-05005-4
Declarations
: AAL participated in advisory board and received speaker and consulting fees from Novartis/AOP/Celgene. MPE participated in advisory board and received speaker fees from Novartis. MIM participated in advisory board and received speaker, consulting fees and support for attending meetings from Incyte/Novartis. FFM received research support from Incyte/CTI and speaker and consulting fees from Novartis/Incyte. VGG received grants from Novartis/BMS, consulting fees from Novartis/BMS, payment for lectures from Novartis/BMS, payment for expert testimony from Novartis/BMS, and support for attending meetings from Novartis/BMS and participated in advisory boards from Novartis/BMS. LF received consulting fees from SierraONC/Novartis/BMS, payment for lectures from Novartis, and support for attending meetings from Novartis/Sanofi. RGD received payment for lectures and expert testimony, and support for attending meetings and participated in advisory boards from Novartis/Jansen/AbbVie. RA received speaker honorarium from Astellas/Celgene/Novartis and participated in advisory board for Novartis/Incyte. BB participated and received speaker and consulting from Novartis. AT, AP, PV, AA, MGC, MTGC, BC, CM, RP, JMR, LG, IM, JCHB, and CS have no conflict of interest to declare.
